B. Riley Financial Varied
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

8.765 +0.155 (+1.80%)
Streaming Delayed Price Updated: 3:35 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 814,051
Open 8.620
Bid (Size) 8.760 (18)
Ask (Size) 8.770 (4)
Prev. Close 8.610
Today's Range 8.500 - 8.990
52wk Range 2.540 - 11.24
Shares Outstanding 44,784,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga

Performance

YTD
+35.1%
+35.1%
1 Month
-1.5%
-1.5%
3 Month
+110.7%
+110.7%
6 Month
+30.2%
+30.2%
1 Year
+233.3%
+233.3%

More News

Read More
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Earnings Scheduled For August 7, 2025
Via Benzinga
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
From Verastem Oncology
Via Business Wire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Via FinancialNewsMedia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
From FN Media Group LLC
Via GlobeNewswire
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
From Verastem Oncology
Via Business Wire
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
Via Benzinga
What's Going On With Verastem Oncology Stock On Monday?
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Via Chartmill
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
Via Benzinga
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased
Via Stocktwits

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 8.765
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 09/26/25 03:35 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 392.53M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 393M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.